Daehan Nupharm Co Ltd

Daehan Nupharm maintains a capital structure with a debt-to-equity ratio of 0.71, indicating moderate leverage relative to its equity base. The company's liquidity position is characterized by a current ratio of 1.55, suggesting it can cover its short-term obligations with its current assets. However, the company's free cash flow is negative at -32.9 billion KRW, and capital expenditures are substantial at -51.1 billion KRW, indicating significant reinvestment in operations. The price-to-book ratio of 0.66 suggests the company is trading at a discount to its book value. Profitability metrics show a return on equity (ROE) of 10.9% and a return on assets (ROA) of 5.63%, which are below the typical thresholds for high-performing pharmaceutical firms. The company's operating margin is 5.8%, calculated from its operating income of 11.7 billion KRW on revenue of 2.024 trillion KRW. These figures suggest that Daehan Nupharm is generating acceptable but not exceptional returns relative to its industry peers. The company's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation implies that the company's performance is closely tied to the Korean market, which could expose it to regional economic fluctuations. Looking at the growth trajectory, the company's revenue in the latest period is 2.024 trillion KRW, but no forward-looking guidance is provided in the input data. The absence of a clear growth narrative or outlook for the next fiscal year makes it difficult to assess the company's future performance with certainty. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its flexibility in responding to market opportunities or downturns. However, the low dilution risk suggests that the company is not expected to issue additional shares in the near term, preserving the value of existing shareholders' equity. There are no recent events or filings mentioned in the input data that would significantly impact the company's operations or financial position. The absence of recent news or disclosures implies a stable but potentially uneventful business environment for Daehan Nupharm.